CTD Holdings, Inc. (OTCMKTS:CTDH) Director Francis Patrick Ostronic bought 100,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were bought at an average price of $0.19 per share, for a total transaction of $19,000.00.

Francis Patrick Ostronic also recently made the following trade(s):

  • On Wednesday, August 28th, Francis Patrick Ostronic bought 50,000 shares of CTD stock. The shares were bought at an average price of $0.20 per share, for a total transaction of $10,000.00.
  • On Wednesday, July 31st, Francis Patrick Ostronic bought 100,000 shares of CTD stock. The shares were bought at an average price of $0.25 per share, for a total transaction of $25,000.00.

Shares of OTCMKTS:CTDH remained flat at $$0.18 during trading on Thursday. The company’s stock had a trading volume of 86,994 shares, compared to its average volume of 141,028. The firm’s 50-day moving average is $0.21 and its 200 day moving average is $0.46. CTD Holdings, Inc. has a 12-month low of $0.16 and a 12-month high of $1.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.74 and a quick ratio of 2.59.

CTD (OTCMKTS:CTDH) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $0.27 million for the quarter. CTD had a negative return on equity of 412.47% and a negative net margin of 565.69%.

CTD Company Profile

CTD Holdings, Inc, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Further Reading: Cost of Debt

Insider Buying and Selling by Quarter for CTD (OTCMKTS:CTDH)

Receive News & Ratings for CTD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTD and related companies with MarketBeat.com's FREE daily email newsletter.